Browse Articles

Discover research articles across all indexed journals

Deep learning to decode sites of RNA translation in normal and cancerous tissues

Nature Communications Jim Clauwaert, Zahra McVey, Ramneek Gupta et al. Feb 02, 2025 DOI: 10.1038/s41467-025-56543-0

Abstract The biological process of RNA translation is fundamental to cellular life and has wide-ranging implications for human disease. Accurate delineation of RNA translation variation represents a significant challenge due to the complexity of the process and technical limitations. Here, we introduce RiboTIE, a transformer model-based approach designed to enhance the analysis of ribosome profiling data. Unlike existing methods, RiboTIE leverages raw ribosome profiling counts directly to robustly detect translated open reading frames (ORFs) with high precision and sensitivity, evaluated on a diverse set of datasets. We demonstrate that RiboTIE successfully recapitulates known findings and provides novel insights into the regulation of RNA translation in both normal brain and medulloblastoma cancer samples. Our results suggest that RiboTIE is a versatile tool that can significantly improve the accuracy and depth of Ribo-Seq data analysis, thereby advancing our understanding of protein synthesis and its implications in disease.

Leveraging the water-environment-health nexus to characterize sustainable water purification solutions

Nature Communications Yu-Li Luo, Yi-Rong Pan, Xu Wang et al. Feb 02, 2025 DOI: 10.1038/s41467-025-56656-6

Abstract Chemicals of emerging concern (CECs) pose critical threats to both public health and the environment, emphasizing the urgent need for effective water treatment measures. Yet, the implementation of such intervention technologies often results in increased energy consumption and adverse environmental consequences. Here, we employ a comprehensive methodology that integrates multiple datasets, assumptions, and calculations to assess the human health and environmental implications of removing various CECs from source water. Our analysis of two treatment alternatives reveals that the integration of riverbank filtration with reverse osmosis offers a promising solution, yielding healthier and more environmentally favorable outcomes than conventional sequential technologies. By incorporating context-specific practices, such as utilizing renewable energy sources and clean energy technologies, we can mitigate the adverse impacts associated with energy-intensive water treatment services. This research advances our understanding of the water-health-environment nexus and proposes strategies to align drinking water provision with public health and environmental sustainability objectives.

FBXO31-mediated ubiquitination of OGT maintains O-GlcNAcylation homeostasis to restrain endometrial malignancy

Nature Communications Na Zhang, Yang Meng, Song Mao et al. Feb 02, 2025 DOI: 10.1038/s41467-025-56633-z

Environment-assisted quantum transport of excitons in perovskite nanocrystal superlattices

Nature Communications Daria D. Blach, Victoria A. Lumsargis-Roth, Chern Chuang et al. Feb 02, 2025 DOI: 10.1038/s41467-024-55812-8

Nuclear ANLN regulates transcription initiation related Pol II clustering and target gene expression

Nature Communications Yu-Fei Cao, Hui Wang, Yong Sun et al. Feb 02, 2025 DOI: 10.1038/s41467-025-56645-9

Structurally convergent antibodies derived from different vaccine strategies target the influenza virus HA anchor epitope with a subset of VH3 and VK3 genes

Nature Communications Ting-Hui Lin, Chang-Chun David Lee, Monica L. Fernández-Quintero et al. Feb 02, 2025 DOI: 10.1038/s41467-025-56496-4

The O-glycosyltransferase C1GALT1 promotes EWSR1::FLI1 expression and is a therapeutic target for Ewing sarcoma

Nature Communications Shahid Banday, Alok K. Mishra, Romana Rashid et al. Feb 02, 2025 DOI: 10.1038/s41467-025-56632-0

Abstract Ewing sarcoma (ES) is an aggressive bone cancer driven by the oncogenic fusion-protein EWSR1::FLI1, which is not present in normal cells and is therefore an attractive therapeutic target. However, as a transcription factor, EWSR1::FLI1 is considered undruggable. Factors that promote EWSR1::FLI1 expression, and thus whose inhibition would reduce EWSR1::FLI1 protein levels and function, are potential drug targets. Here, using genome-scale CRISPR/Cas9 knockout screening, we identify C1GALT1, a galactosyltransferase required for the biosynthesis of many O-glycoproteins, as a factor that promotes EWSR1::FLI1 expression. We show that C1GALT1 acts by O-glycosylating the pivotal Hedgehog (Hh) signaling component Smoothened (SMO), thereby stabilizing SMO and stimulating the Hh pathway, which we find directly activates EWSR1::FLI1 transcription. Itraconazole, an FDA-approved anti-fungal agent that is known to inhibit C1GALT1, reduces EWSR1::FLI1 levels in ES cell lines and suppresses growth of ES xenografts in mice. Our study reveals a therapeutically targetable mechanism that promotes EWSR1::FLI1 expression and ES tumor growth.

Single-cell transcriptomics analysis reveals dynamic changes and prognostic signature in tumor microenvironment of PDAC

Scientific Reports Yongsheng Li, Zhilong Ding, Tingxin Cheng et al. Feb 02, 2025 DOI: 10.1038/s41598-025-86950-8

Improving photovoltaic water pumping system performance with ANN-based direct torque control using real-time simulation

Scientific Reports Ikram Saady, Btissam Majout, Ismail El Kafazi et al. Feb 02, 2025 DOI: 10.1038/s41598-025-88330-8

Abstract Photovoltaic Water Pumping Systems (PVWPS) have become increasingly important as a renewable energy solution in rural areas, providing energy independence, cost savings, and environmental friendliness. This system has two main controllers. The first controller is employed to maximize power extraction from the PV array by controlling the duty ratio of the DC-DC boost converter. The second controller is responsible for regulating the operation of the induction motor through the switching pulses of the Voltage Source Inverter (VSI). These two controllers play an essential role in the system, which increases efficiency and performance. Therefore, the innovative aspect of this work consists of introducing Artificial Neural Networks (ANNs) based on each PVWPS controller. On the one hand, ANN-based MPPT is implemented to ensure optimal performance of the PV array under varying irradiation levels. On the other hand, to overcome the defects and problems caused by Direct Torque Control (DTC), such as flux and torque ripples, high switching frequency, and challenges at low speeds, an ANN-based DTC is proposed in which each of the hysteresis comparators, switching table, and speed controller in the DTC are replaced by ANN controllers. The PVWPS based on the proposed controls is thoroughly modeled and simulated using MATLAB/Simulink software and validated using dSPACE DS1104 Board. The results demonstrate significant improvements, including a 75.51% reduction in flux ripples, a 77.5% reduction in torque ripples, a 44.79% improvement in response time, and an increase in the water quantity. Furthermore, the Real-Time simulation and visualization obtained are consistent with the simulation outcomes.

Beta-hydroxy-beta-methylbutyrate (HMB) improves daily activity and whole-body protein metabolism in Duchenne muscular dystrophy dogs: a pilot study

Scientific Reports Peter P. Nghiem, Alexis M. Rutledge, Kyle Tehas et al. Feb 02, 2025 DOI: 10.1038/s41598-025-88651-8

Life-cycle assessment of oil recovery using dimethyl ether produced from green hydrogen and captured CO2

Scientific Reports R. Farajzadeh, N. Khoshnevis, D. Solomon et al. Feb 02, 2025 DOI: 10.1038/s41598-025-87981-x

Quantum secure patient login credential system using blockchain for electronic health record sharing framework

Scientific Reports M. Natarajan, A. Bharathi, C. Sai Varun et al. Feb 02, 2025 DOI: 10.1038/s41598-025-86658-9

A theoretical prediction for generating isolated attosecond pulse in water window utilizing instantaneous frequency change of two-color driving laser pulse

Scientific Reports Masoumeh Dehghanian, Mohammad Sabaeian, Siamak Noorizadeh Feb 01, 2025 DOI: 10.1038/s41598-025-88665-2

Elucidating ligand interactions and small-molecule activation in the pyrrolnitrin biosynthetic enzyme PrnB

Journal of Biological Chemistry Bingnan Li, Remigio Usai, Jackson Campbell et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2024.108123

A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with localized disease from the Spanish RETUD registry.

Journal of Clinical Oncology Ana Fernandez Fernandez Montes, Carolina Muriel Lopez, Sandra Lopez et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.173

173 Background: Microsatellite instability (MSI) localized colorectal cancer (CRC) constitutes a subgroup of patients (pts) with different clinical and molecular characteristics and prognosis compared to microsatellite stable (MSS) disease. Here, we present our real world data regarding the management and clinical outcomes of a cohort of MSI-h localized CRC patients included in the Spanish Group of Treatment of Digestive Tumors (TTD) Registry (RETUD). Methods: RETUD is a national, multicenter registry for gastrointestinal tumors from the Spanish TTD Group. In this cross-sectional analysis we evaluated a real-world cohort of MSI-h localized CRC pts diagnosed from 1 st January 2017 to 29 th April 2024. Baseline characteristics and neo/adjuvant treatments are descriptively presented. Disease-free survival (DFS) and overall survival (OS) analyzed by Kaplan-Meier method are presented along with 95% confidence intervals (CI). Results: Five hundred and sixty-one (561) evaluable pts out of 679 MSI-CRC included in RETUD had a localized disease as initial diagnosis. Pts had a median age of 73.1 years and were predominantly Caucasian (97.7%) and female (52.6%). Fifty (12.4%) pts had Lynch Syndrome. Main tumor baseline characteristics are described (Table). Local-locoregional therapeutic procedures were: primary tumor resection in 531 (99.1%) pts and radiotherapy in 18 (3.2%) pts. A total of 198 (35.3%) pts received systemic therapy, mostly chemotherapy (n=165 83.3%) but 18 (9.1%) were treated with pembrolizumab due to unresectable disease. At database cut-off, 123 (21.9%) patients died, mostly due to not related intercurrent illness, and 96 (17.1%) pts developed metastasis. After a median follow up period of 28.5 months, the median (95% CI) OS was not reached and DFS was 78.2 (55.4-NA) months. The impact of adjuvant systemic therapy (chemotherapy vs. non-chemotherapy) for both stage II and stage III pts is under evaluation. Conclusions: Our work provides valuable real-world data from a cohort of MSI-h localized CRC pts treated under clinical practice conditions in Spain, reiterating the good disease prognosis exhibited by this subset of pts in contrast to MSS pts. Main tumor characteristics. Stage at initial diagnosis, n (%) I/II n (%) 55 (9.8) / 258 (46.0) III, n (%) 248 (44.2) Location of primary tumor a , n (%) right colon /left colon /rectum 447 (78.4) / 82 (14.4) / 41 (7.2) Type histological b , n (%) Intestinal 271 (48.9) Mucinous (colloid) adenocarcinoma (>50% mucinous) 115 (20.8) Signet ring cell carcinoma (>50% signet ring) 14 (2.5) Medullary carcinoma 18 (3.2) a Pts with more than 1 primary tumor; the percentage may be over 100%. b Unknown histology in 132 (23.8%) pts and missing data in 7 pts.

TAS102 in combination with oxaliplatin (TASOX) for refractory metastatic colorectal cancer.

Journal of Clinical Oncology Sharon Li, Fan Ling, Christian Misdary et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.189

189 Background: TAS102 (trifluridine/tipiracil hydrochloride) is approved for use alone or with bevacizumab in late line metastatic colorectal cancer (mCRC), with overall survival benefit in phase 3 trials (RECOURSE and SUNLIGHT). Oxaliplatin is frequently reintroduced after progression, resolution of limiting neuropathy, or disease recurrence post adjuvant therapy. In preclinical studies, oxaliplatin combined with TAS102 has shown synergism. We hypothesized TASOX may be an option for patients who have progressed/recurred after FOLFOX. Methods: We assessed safety and efficacy of TAS102 with oxaliplatin, enrolling patients with metastatic CRC progressed on ≥2 lines of therapy including 5FU, oxaliplatin and irinotecan. Patients with recurrence during or within 6 months of adjuvant chemotherapy were allowed. Exclusion: Prior TAS102 exposure, functional impairing peripheral neuropathy, ≥Grade 3 hypersensitivity to oxaliplatin, or uncontrollable grade 1-2 hypersensitivity to oxaliplatin. Treatment continued until disease progression or unacceptable toxicity. Patients received oxaliplatin 85 mg/m2 and TAS-102 35 mg/m2 bid days 1-5 every two weeks, and bevacizumab per MD choice. The primary endpoint was overall response rate (ORR) by RECIST (by independent radiologists). Secondary endpoints included disease control rate (DCR), safety and tolerability. Results: 54 patients enrolled; 53 received treatment on study and 48 had ≥1 disease assessment (median age 59, 58 % male, tumor RAS mutated 69%). Median time on study was 4 months (8 cycles; range 1-37 cycles). ORR was 6% (n=3), with average change in target lesions -45% (range -35 to -67%). 71% (n=34) had SD defined on study, with average change in target lesions -3% (range -29% to +20%). In those treated with bevacizumab (59%; n=28 ), 79% (n=22) had disease control vs. 75% (n=15). The most common reason for study discontinuation was progressive disease (23%, n=11). 68% (n=36) had a treatment-related adverse event (TRAE) ≥Grade 3 at any point during therapy. The most common G3 TRAEs were anemia 19% (n=10) and leukopenia 28% (n=15) at any time. Two (4%) developed grade 3 neuropathy. Conclusions: TASOX is effective as a 3rd line therapy for patients with mCRC. In our study, overall disease control rate was 77% with up to 19 months on study. Anemia and leukopenia are common but manageable. Bevacizumab did not seem to have as great an effect in our trial as observed in SUNLIGHT. Future studies would warrant TASOX in combination to bevacizumab in randomized trials in candidates for oxaliplatin retreatment. Clinical trial information: NCT02848079 .

Efficacy of immune checkpoint inhibitors in patients with advanced pancreatic NETs displaying high TMB and MMR alterations following treatment with alkylating agents.

Journal of Clinical Oncology Jonathan R. Strosberg, Anna Koumarianou, Rachel Riechelmann et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.662

662 Background: Alkylating-based chemotherapy (ALK) is one of the main treatments used in patients with advanced pancreatic neuroendocrine tumors (PanNETs). Its use has been associated with an increased risk of grade progression and acquisition of a hypermutator phenotype, associated with frequent alterations of the mismatch repair (MMR) genes. This suggests a potential benefit of immune checkpoint inhibitors (ICI) that are otherwise ineffective in ALK-naïve PanNETs, which are mostly hypomutated. We aimed to describe the efficacy of ICI in patients with advanced PanNET pretreated with ALK. Methods: We assembled an international retrospective cohort of patients with advanced PanNET who received at least one cycle of ICI, and who had previously received at least 3 months of ALK. Patients with poorly-differentiated neuroendocrine carcinoma were excluded. The primary endpoint was progression-free survival (PFS) and the secondary endpoint was the objective response rate (ORR). The impact of tumor mutational burden (TMB, high being defined by >10 mut/Mb) and MMR alterations (mutations or IHC) was explored. Results: We included 39 patients (median age 58.7, male sex 62%). All PanNETs were progressive at baseline and presented a median of 3 (IQR, 2-4) metastatic sites. Tumors were predominantly classified as G2 (47%) or G3 (42%), with a median Ki-67 of 18.5% (IQR, 12-35). 23/27 patients with tumor tissue or ctDNA NGS testing had high TMB (median, 35 mut/Mb; IQR, 24-106) and 12/22 had MMR alterations. Patients had previously received an average of 14 cycles (IQR, 7-25) of ALK (temozolomide 78%, streptozotocin 18%, dacarbazine 4%), which had yielded objective response in 72% of cases. In addition, patients had received a median of 4 (IQR, 3-5) other treatments (including platinum drugs in 80% and PRRT in 51%). ICI mainly consisted in an anti-PDL1/PD1 + anti-CTLA4 combination (85%) or a monotherapy (15%), with a median of 3 (IQR, 2-8) cycles. The ORR was 18% and the disease control rate was 46%. Median PFS was 2.8 months (95% CI, 0.62-4.96) and 6-month PFS rate was 31%. 19% of patients had grade 3-4 toxicity. Patients with high TMB had higher ORR (30% vs. 0%, p=0.03) and longer median PFS (4.9 vs. 2.1 months, p=0.004) compared with patients with low/unknown TMB. Patients with altered MMR had higher ORR (42% vs. 7%, p=0.02) and longer median PFS (8.9 vs. 2.5 months, p=0.014) compared with patients with no/unknown MMR alterations. Conclusions: While ICI shows limited efficacy in unselected patients with advanced PanNETs pretreated with ALK, it may be an effective treatment option in case of high TMB and MMR alterations.

VO2 based polarization-independent dual-wavelength plasmonic switches using U and C shaped nanostructures

Scientific Reports Kirti Dalal, Yashna Sharma Feb 01, 2025 DOI: 10.1038/s41598-025-85349-9

PTEN loss in glioma cell lines leads to increased extracellular vesicle biogenesis and PD-L1 cargo in a PI3K-dependent manner

Journal of Biological Chemistry Julio C. Sanchez, Timothy M. Pierpont, Dariana Argueta-Zamora et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2024.108143

Neoadjuvant cadonilimab plus anlotinib followed by surgery for locally advanced esophageal squamous cell carcinoma: A single arm, phase 2 trial.

Journal of Clinical Oncology Wenhan Weng, Heng Zhao, Jiayi Geng et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.tps506

TPS506 Background: Esophageal cancer (EC) is the seventh most common cancer in China, where most of patients have locally advanced esophageal squamous cell carcinoma (LA-ESCC) at the time of diagnosis. Neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) followed by surgery is standard treatment strategy for LA-ESCC in China. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of ESCC. Programmed death 1 (PD-1) inhibitors are the most commonly used ICIs in treatment of ESCC. Lately, the phase 3 ESCORT-NEO/NCCES01 trial demonstrates that neoadjuvant PD-1 inhibitor plus chemotherapy obtains superior pCR rates compared to chemotherapy alone for LA-ESCC. Except for PD-1 inhibitors, cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitor is another effective ICI for ESCC, especially combined with PD-1 inhibitor according to the CHECKMATE-648 study. Although neoadjuvant immunotherapy plus chemotherapy has brought earth-shaking changes to the treatment of LA-ESCC, the chemo-based treatment modality still results in a high incidence of adverse events, reduces the quality of life and compliance of patients. Cadonilimab is a dual immune antibody drug comprised of PD-1 antibody and CTLA-4 antibody. Anlotinib is an oral, small molecule anti-angiogenic targeted agent that has been approved for use in advanced or metastatic ESCC in China. Therefore, we launched this trial to assess the efficacy and safety of cadonilimab plus anlotinib, a novel "chemo-free" strategy, followed by surgery for LA-ESCC. Methods: Study design: This is a single-arm, phase 2 study (NCT06426797). The primary endpoint of this study is the pCR rate. The secondary endpoints include safety, major pathological response (MPR) rate, objective response rate (ORR), R0 resection rate, and event-free survival (EFS). Study procedures: Cadonilimab will be intravenously administered at day 1 with a dose of 10 mg/Kg every three weeks for three cycles. Anlotinib will be orally administered daily at day 1 to day 14 with a dose of 12mg every three weeks for three cycles. In the end, the subjects will receive subtotal esophagectomy 4 to 6 weeks later after the last dose of cadonilimab. Major inclusion criteria: 1. Age > 18 years. 2. Histopathologically confirmed ESCC: c-stage II–IVA (8 th ed. AJCC). 3. Enough tissue for PD-L1 IHC test. 4. Eligible for anlotinib treatment. 5. ECOG performance status ≤ 2 points. Statistics: We hypothesized that the expected pCR rate would be 50%. 24 subjects are needed at an α-level of 0.05 (one-sided) and power of 80%. So, 25 subjects in total should be enrolled. The descriptive statistical method will be applied to the presentation of baseline characteristics, toxicities and measures of effectiveness. The Kaplan–Meier method will be used to calculate survival rates. Current enrollment: The study started on August 1 st , 2024, and 3 of planned 25 patients have been enrolled. Clinical trial information: NCT06426797 .